Validation of the Double-Hit Gene Expression Signature (DLBCL90) in an Independent Cohort of Patients with Diffuse Large B-Cell Lymphoma of Germinal Center Origin

Autor: Dennis D. Weisenburger, Alex F. Herrera, David Scott, Minlin Xu, Wing C. Chan, Joyce Murata-Collins, Victoria Bedell, Pamela Skrabek, Michel R. Nasr, Lu Chen, Ha Nguyen, Joo Y. Song, Raju Pillai, Anamarija M. Perry
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
Double hit
DNA Copy Number Variations
Cell of origin
Translocation
Genetic
Pathology and Forensic Medicine
Cohort Studies
03 medical and health sciences
0302 clinical medicine
immune system diseases
hemic and lymphatic diseases
Gene expression
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Tumor
Medicine
Humans
In Situ Hybridization
Fluorescence
Gene Rearrangement
medicine.diagnostic_test
business.industry
Germinal center
Regular Article
Middle Aged
medicine.disease
Germinal Center
Prognosis
Lymphoma
Survival Rate
030104 developmental biology
030220 oncology & carcinogenesis
Cohort
Mutation
Cancer research
Molecular Medicine
Female
Lymphoma
Large B-Cell
Diffuse
business
Transcriptome
Diffuse large B-cell lymphoma
Fluorescence in situ hybridization
Follow-Up Studies
Zdroj: J Mol Diagn
Popis: The prognosis of diffuse large B-cell lymphoma (DLBCL) has been associated with clinical parameters, cell of origin, and various genetic aberrations. Recently, a NanoString gene expression assay (DLBCL90) was developed, which identifies DLBCL cases with an outcome similar to those with double- or triple-hit DLBCL with both MYC and BCL2 rearrangements. This study validates the predictive ability of the DLBCL90 assay in an independent cohort of patients with the germinal center B-cell subtype DLBCL. A customized targeted sequencing panel was used to analyze the mutational profile in these patients. Cases with a double or triple hit by conventional fluorescence in situ hybridization cytogenetic analysis are known to have a poor prognosis, and the DLBCL90 gene expression signature identified these cases, as well as additional cases that would have otherwise been missed by fluorescence in situ hybridization analysis. Our findings validate use of the DLBCL90 assay for identifying high-risk patients for new and innovative therapies.
Databáze: OpenAIRE
Externí odkaz: